CYTOSORBENTS CORP (CTSO) Stock Price, Quote, News and Overview
NASDAQ:CTSO - Nasdaq - US23283X2062 - Common Stock - Currency: USD
CTSO Quote, Performance and Key Statistics
1.22
+0.04 (+3.39%)
The current stock price of CTSO is 1.22 USD. In the past month the price increased by 17.31%. In the past year, price increased by 24.49%.
CTSO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.29 | 229.17B | ||
| ISRG | INTUITIVE SURGICAL INC | 83.01 | 217.02B | ||
| BSX | BOSTON SCIENTIFIC CORP | 42.1 | 155.74B | ||
| SYK | STRYKER CORP | 31.87 | 148.11B | ||
| MDT | MEDTRONIC PLC | 16.29 | 111.56B | ||
| BDX | BECTON DICKINSON AND CO | 16.36 | 65.34B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.5 | 44.04B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.61 | 42.27B | ||
| IDXX | IDEXX LABORATORIES INC | 40.09 | 36.93B | ||
| DXCM | DEXCOM INC | 54.35 | 35.03B | ||
| RMD | RESMED INC | 26.53 | 34.44B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.28 | 23.55B |
Related stock screener links
About CTSO
Company Profile
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 186 full-time employees. The company went IPO on 2005-06-17. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Company Info
CYTOSORBENTS CORP
305 College Road East
Princeton NEW JERSEY 08852 US
CEO: Phillip P. Chan
Employees: 186
Company Website: https://cytosorbents.com/
Investor Relations: https://cytosorbents.com/investor-relations/overview
Phone: 19733298885
CTSO FAQ
What is the stock price of CTSO?
The current stock price of CTSO is 1.22 USD.
What is the symbol for CYTOSORBENTS CORP stock?
The exchange symbol of CYTOSORBENTS CORP is CTSO and it is listed on the Nasdaq exchange.
On which exchange is CTSO stock listed?
CTSO stock is listed on the Nasdaq exchange.
Is CTSO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CTSO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CTSO.
Does CTSO stock pay dividends?
CTSO does not pay a dividend.
When does CTSO stock report earnings?
CTSO will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of CTSO?
CTSO does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
What is the Short Interest ratio of CTSO stock?
The outstanding short interest for CTSO is 3.9% of its float.
CTSO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CTSO. When comparing the yearly performance of all stocks, CTSO is one of the better performing stocks in the market, outperforming 88.14% of all stocks.
CTSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTSO. CTSO has a bad profitability rating. Also its financial health evaluation is rather negative.
CTSO Financial Highlights
Over the last trailing twelve months CTSO reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 31.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.06% | ||
| ROE | -143.63% | ||
| Debt/Equity | 1.06 |
CTSO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CTSO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 53.45% and a revenue growth 5.35% for CTSO